Parameters of clozapine treatment in patients with treatment-resistant Schizophrenia

Abstract

Treatment-resistant schizophrenia (TRS) is familiar to one in three schizophrenia patient and clozapine is referred as only drug which has the approval for the remedy of TRS. After identifying TRS, clozapine treatment should not be delayed in order to achieve remission. Long delays of prescribing clozapine take place because of the concern over adverse effects, proper monitoring procedure and inexperience at prescribing. For this reason, patients do not achieve favorable outcomes and they are exposed to unnecessary health risks. In this study, clozapine use in TRS, guidelines and strategies to overcome risks and initiate early treatment literature are reviewed. Based on all of these, a review of parameters of clozapine treatment in TRS patients has been summarized in this study with proper evidence.